Modus Therapeutics Holding

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.

Modus’ largest owners are Karolinska Development (Nasdaq Stockholm: KDEV), KDev Investments AB, (jointly owned by Karolinska Development AB and Rosetta Capital) and John Öhd. The company has been listed on the Nasdaq First North Growth Market since July 2021.